View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Mar. 31, 2020	Jun. 08, 2020	Sep. 30, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Olivia Ventures, Inc.
Entity Central Index Key	0001738021
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Type	10-K
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Ex Transition Period	false
Entity Small Business	true
Entity Shell Company	true
Entity Emerging Growth Company	true
Entity Common Stock, Shares Outstanding		5,000,000
Entity Filer Number	000-55939
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Public Float			$ 0

Balance Sheets - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Current assets
Cash	$ 3,745	$ 4,866
Total current assets	3,745	4,866
Total assets	3,745	4,866
Current liabilities
Accrued expenses	8,707	3,330
Note payable - stockholder	103,110	72,125
Total current liabilities	111,817	75,455
Total liabilities	111,817	75,455
Stockholders' deficit
Preferred stock, $.0001 par value, 5,000,000 shares authorized; none issued and outstanding
Common stock, $.0001 par value, 50,000,000 authorized shares; 5,000,000 shares issued and outstanding	500	500
Accumulated deficit	(108,572)	(71,089)
Total stockholders' deficit	(108,072)	(70,589)
Total liabilities and stockholders' deficit	$ 3,745	$ 4,866

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Mar. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ .0001	$ .0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ .0001	$ .0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	5,000,000	5,000,000
Common stock, shares outstanding	5,000,000	5,000,000

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenue
General and administrative expenses	32,105	32,759
Loss from operations	(32,105)	(32,759)
Other expenses
Interest expense	5,378	3,278
Net loss	$ (37,483)	$ (36,037)
Loss per common share - basic and dilutive	$ (0.01)	$ (0.01)
Weighted average common shares outstanding - basic and dilutive	5,000,000	5,000,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Statements of Changes in Stockholders’ (deficit) - USD ($)	Common Stock	Accumulated Deficit	Total
Balance at Mar. 31, 2018	$ 500	$ (35,052)	$ (34,552)
Balance, Shares at Mar. 31, 2018	5,000,000
Net loss		(36,037)	(36,037)
Balance at Mar. 31, 2019	$ 500	(71,089)	(70,589)
Balance, Shares at Mar. 31, 2019	5,000,000
Net loss		(37,483)	(37,483)
Balance at Mar. 31, 2020	$ 500	$ (108,572)	$ (108,072)
Balance, Shares at Mar. 31, 2020	5,000,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (37,483)	$ (36,037)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Increase in accrued expenses	5,377	3,278
Net cash (used in) operating activities	(32,106)	(32,759)
Cash flows from financing activities:
Collection of stock subscription receivable		25
Proceeds from note payable - stockholder	30,985	37,600
Net cash provided by financing activities	30,985	37,625
Net (decrease) increase in cash	(1,121)	4,866
Cash, beginning of year/period	4,866
Cash, end of year/period	$ 3,745	$ 4,866

Basis of Presentation and Summary of Significant Accounting Policies

12 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents are reported in the balance sheets at cost, which approximates fair value. For the purpose of the financial statements, cash equivalents include all highly liquid investments with maturity of three months or less. There are no cash equivalents at the balance sheet dates.

Income Taxes

The Company adopted ASC 740, Income Taxes, at its inception. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry-forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Loss per Common Share

Basic loss per common share has been calculated by dividing the Company's net loss available to common stockholders by the weighted average number of common shares outstanding during the year. The diluted (loss) per share is calculated by dividing the Company's net loss available to common stockholders by the diluted weighted average number of shares outstanding for the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

Emerging Growth Company

The Company is an "emerging growth company" and has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies.

Recently Issued Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Income Taxes

12 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

Note 3 - Income Taxes

As of March 31, 2020 and 2019, the Company has net operating loss carryforwards (NOLs) of approximately $109,000 and $71,000 respectively, to reduce future federal and state taxable income through 2039 subject to the change in ownership provisions under IRC 382. These NOLs result in a deferred tax asset as of March 31, 2020 and 2019, of approximately $23,000 and $15,000, respectively, against which a full valuation allowance has been recorded because the Company's management believes future realization of the related income tax benefit is uncertain.

The Company currently has no federal or state tax examinations in progress nor has it had any federal or state examinations since its inception. All of the Company's tax years are subject to federal and state tax examination.

On December 22, 2017, the enactment date, the Tax Cuts and Jobs Act ("Act") was signed into law. The Act effectively reduces the top corporate tax rate from 35 percent to a flat 21 percent beginning January 1, 2018 and eliminates the corporate Alternative Minimum Tax. The Company has adjusted its deferred tax calculations to reflect this reduction in its tax rate.

The benefit from income taxes consists of the following:

	Year Ended March 31, 2020			Year ended March 31, 2019
Current expense:
Federal	$	-		$	-
Deferred tax benefit:
Federal		(7,900	)		(7,600	)
Valuation allowance		7.900			7,600
Total	$	-		$	-

The difference between the tax provision at the statutory federal income tax rate on March 31, 2020 and 2019, and the tax provision attributable to loss before income taxes is as follows:

	Year Ended March 31, 2020			Year ended March 31, 2019
Statutory federal income tax rates		21	%		21	%
Valuation allowance		-21	%		-21	%
Effective tax rate, net		-			-

Subsequent Events

12 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

Note 8 – Subsequent Events

On May 27, 2020, the Company filed with the SEC, and on May 28, 2020, it amended, a Schedule 14F-1 Information Statement relating to an anticipated change in the composition of its board of directors that is expected to occur in connection with a proposed merger to be completed by and among the Company, a to-be-formed wholly-owned subsidiary of the Company ("Merger Sub"), and Compass Therapeutics LLC, a Delaware limited liability company ("Compass"), pursuant to which Merger Sub would merge with and into Compass, with Compass continuing as the surviving entity (the "Merger") and as the Company's wholly-owned subsidiary, after which the Company would continue the business of Compass. The Merger would occur pursuant to an Agreement and Plan of Merger and Reorganization expected to be entered into by and among the Company, Compass and Merger Sub (the "Merger Agreement").

Compass is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics.

Pursuant to the terms of the proposed Merger Agreement, it is expected that all outstanding limited liability company membership units of Compass will be converted into shares of our Common Stock, such that the holders of Compass equity before the proposed Merger will own more than 95% of the outstanding shares of our Common Stock after the Merger (before giving effect to a potential private placement offering of Common Stock by the Company that we expect will be consummated simultaneously with or immediately after the proposed Merger), resulting in a change of control of the Company. Completion of a private placement financing is expected to be a condition to completion of the Merger.

Certain other information regarding the proposed Merger and proposed changes to the management and share ownership of the Company is set forth in the Schedule 14F-1, as amended.

The foregoing description of the proposed Merger Agreement and potential Common Stock private placement and related matters does not purport to be complete and is qualified in its entirety by the terms of the actual Merger Agreement and of terms and documentation for a private placement, none of which has yet been completed and executed. The proposed Merger is expected to be subject to satisfaction of a number of other conditions precedent, and there can be no assurance that the Merger Agreement will be signed or that the Merger or Common Stock private placement will be consummated or other such conditions satisfied. If and when the Merger Agreement is signed, it will be further described in and filed by the Company with the SEC as an exhibit to a Current Report on Form 8-K. If and when a Common Stock private placement is consummated, it will be further described in, and material agreements relating thereto will be filed by the Company with the SEC as exhibits to, a Current Report on Form 8-K.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are reported in the balance sheets at cost, which approximates fair value. For the purpose of the financial statements, cash equivalents include all highly liquid investments with maturity of three months or less. There are no cash equivalents at the balance sheet dates.
Income Taxes	Income Taxes The Company adopted ASC 740, Income Taxes, at its inception. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry-forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Loss per Common Share	Loss per Common Share Basic loss per common share has been calculated by dividing the Company's net loss available to common stockholders by the weighted average number of common shares outstanding during the year. The diluted (loss) per share is calculated by dividing the Company's net loss available to common stockholders by the diluted weighted average number of shares outstanding for the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.
Emerging Growth Company	Emerging Growth Company The Company is an "emerging growth company" and has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327

+ Details

Income Taxes (Tables)

12 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of provision for income taxes

	Year Ended March 31, 2020			Year ended March 31, 2019
Current expense:
Federal	$	-		$	-
Deferred tax benefit:
Federal		(7,900	)		(7,600	)
Valuation allowance		7.900			7,600
Total	$	-		$	-

Schedule of effective income tax rate and the U.S. federal income tax rate

	Year Ended March 31, 2020			Year ended March 31, 2019
Statutory federal income tax rates		21	%		21	%
Valuation allowance		-21	%		-21	%
Effective tax rate, net		-			-

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Current expense:
Federal
Deferred tax benefit:
Federal	(7,900)	(7,600)
Valuation allowance	7,900	7,600
Total

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Statutory federal income tax rates	21.00%	21.00%
Valuation allowance	(21.00%)	(21.00%)
Effective tax rate

Capital Stock (Details) - $ / shares	Mar. 31, 2020	Mar. 31, 2019
Capital Stock (Textual)
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ .0001	$ .0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ .0001	$ .0001
Common stock, shares issued	5,000,000	5,000,000
Common stock, shares outstanding	5,000,000	5,000,000

Commitments and Related Party Transactions (Details) - USD ($)	1 Months Ended
	Mar. 22, 2018	Mar. 31, 2020	Mar. 31, 2019
Commitments and Related Party Transactions (Textual)
Interest rate, description	Interest shall accrue on the outstanding principal amount of the Note on the basis of a 360-day year from the date of borrowing until paid in full at the rate of six percent (6%) per annum.
Total amount due		$ 111,817	$ 75,455
Accrued interest		$ 8,707	$ 3,330

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

Going Concern (Details) - USD ($)	12 Months Ended
Going Concern (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Going Concern (Textual)
Negative working capital	$ 108,000
Incurred losses from inception	109,000
Stockholders' deficit	$ (108,072)	$ (70,589)	$ (34,552)

Income Taxes (Details Textual) - USD ($)	1 Months Ended
Income Taxes (Details Textual) - USD ($)	Dec. 22, 2017	Mar. 31, 2020	Mar. 31, 2019
Income Taxes (Textual)
Net operating loss carryforwards		$ 109,000	$ 71,000
Deferred tax asset valuation allowance		$ 23,000	$ 15,000
Net operating loss carryforwards, description	The enactment date, the Tax Cuts and Jobs Act ("Act") was signed into law. The Act effectively reduces the top corporate tax rate from 35 percent to a flat 21 percent beginning January 1, 2018 and eliminates the corporate Alternative Minimum Tax.